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Abstract 
Metformin-associated lactic acidosis (M-ALA) is considered to be one of the complications caused by intravascular 
contrast media (CM) administration in diabetics especially those with coexisting renal or cardiac impairment. We 
focused on the necessity and duration of metformin suspension in diabetics with normal or impaired renal function 
scheduled for CT scan with IV contrast. Searching PubMed, Web of Science, and Scopus databases, we reviewed the 
latest relevant guidelines as well as articles published from 1994 to 2015. There is no global consensus among 
different guidelines on the duration of the Metformin suspension before CT scan with IV contrast. Also, lack of 
substantial evidence supporting M-ALA encourages specialists to take a less conservative approach. 
It is safe to continue Metformin in patients with normal renal function who have no co-morbidities. In cases of 
equivocal renal function (30<GFR<60 mL/min/1.73 m
2
) and also in patients with normal renal function and other co-
morbidities, the decision should be made based on the patient‘s clinical status. In case of severe renal failure, the use 
of metformin should be reassessed. Due to the probability of contrast associated nephropathy, laboratory follow up 
seems to be necessary for all patients. 
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Introduction 
Metformin is a biguanide used mainly as an oral 
hypoglycaemic agent in the treatment of type 2 diabetes 
mellitus
1
. The most significant adverse effect of 
metformin therapy is the potential for lactate 
accumulation and development of metformin-associated 
lactic acidosis (M-ALA). M-ALA occurs under 
circumstances include reduced lactate metabolism like 
hepatic dysfunction or alcohol abuse, increased anaerobic 




The incidence of M-ALA appears to be low
3,4
. In surveys 
from Europe, the US and Canada, the estimated 
incidence of M-ALA in patients with type 2 diabetes was 
2–10/100,000 patient–years
5,6
. According to a Cochrane 
meta-analysis, considering an upper 95% confidence 
interval, the incidence of LA in 70,490 patient–years in 
metformin-treated patients and 55,451 patient–years in 
non-metformin-treated patients was 4.3/100,000 and 
5.4/100,000, respectively
3
. The incidence of LA or 
elevated lactate concentrations in current metformin 
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users with renal impairment is estimated to be 
7.4/100,000 person–years (vs 2.2/100,000 person–years 
in non-users)
7
. However, incidence of MALA 
accompany with cardiac or renal impairment might be 
higher up to 47 per 100,000 according to a more recent 
study
8
. Despite its rarity, M-ALA remains a concern 
because of its high mortality rate (50%), which mainly 
occurs in patients predisposed to hypoperfusion and 
hypoxaemia (acute or progressive renal impairment or 




Sedentary lifestyle and increased life expectancy in 
recent decades have led to greater consumption of 
metformin because of the increased prevalence of type 2 
diabetes mellitus. There has been an increase in 
availability of advanced imaging technologies using 
intravascular contrast media (CMs), as wells as their 
indications and prescription
10
. Careful planning is 
required before using these procedures to avoid potential 
adverse reactions and complications arising from reckless 
use of intravascular contrast agents in susceptible 
patients. Patients taking metformin are encountered daily 
in busy imaging departments. There is no known 
interaction between metformin and intravascular CMs, 
and metformin itself is not a nephrotoxic agent
10
. The 
link between metformin, contrast medium and the risk of 
lactic acidosis (LA) is considered to be a potential factor 
which leads to renal impairment. Contrast-induced 
nephropathy increases the risk of metformin 
accumulation, thus the potential for LA; its incidence is 
estimated to range from 0.1% to 13% with preexisting 
renal impairment as an important risk factor
11
.  
The constantly changing nature of medicine and increase 
in research evidence mandates periodic revision and 
drafting of new guidelines for the safe use of intravenous 
CMs in special clinical scenarios, including patients on 
metformin. One of the most frequent questions asked by 
radiologists is whether metformin should be discontinued 
in patients receiving intravascular CMs. However, there 
is no general consensus in the literature and guidelines 
developed by different countries and no solid 
unequivocal evidence on the matter. 
Methods 
All relevant guidelines in the English-language medical 
literature were reviewed, including those of the American 
College of Radiology, Royal Australian and New 
Zealand College of Radiologists, Royal College of 
Radiologists, Canadian Association of Radiologists and 
European Society of Urogenital Radiology. We searched 
PubMed, Web of Science and Scopus for articles and 
guidelines on metformin discontinuation in patients 
receiving intravenous CMs and risk of LA. We analysed 
relevant articles in English, between 1994 and 2015, and 
focused on the necessity and duration of metformin 
suspension before administration of intravenous CMs in 
patients with diabetes with normal or impaired renal 
function. Key words were ‗metformin‘, ‗lactic acidosis‘, 
‗contrast media‘ and ‘CT scan‘. 
Evidence for M-ALA after exposure to CMs: LA has 
been reported in patients with diabetes who do not taking 
metformin; typically secondary to underlying conditions 
in which there has been significant tissue hypoxia, such 
as acute left ventricular failure
10,12
. This implies that 
metformin is not the only factor to cause acidosis. 
Also, in a large randomized controlled trial, which was 
planned to assess the comparative outcomes of 
metformin use versus conventional approach, the 
researchers compared the outcomes in diabetics taking 
metformin with the outcomes in other people who 
underwent non-metformin monotherapy or combination 
therapy in one year interval; according to the results, no 
case of lactic acidosis was observed, and plasma lactate 
did not differ between patients undergoing these two 
methods. The COSMIC study suggests that metformin 




This finding is in line with another meta-analysis on M-
ALA, which used pooled data derivated from 347 
prospective comparative trials and observational cohort 
studies. The authors found no cases of fatal or nonfatal 
LA in 70,490 patient–years of metformin use or in 
55,451 patient–years in the non-metformin group. The 
mean blood lactate level during metformin treatment was 
not significantly different from that in patients receiving 
medications other than metformin. The authors 
concluded, compared to other anti-hyperglycemic 
treatments, there was no evidence suggesting a link 
between metformin and an increased risk of lactic 
acidosis, or increased lactate
3
.  
M-ALA is a rare event. Among about the first million 
patients who have received metformin in the United 
States, only 47 cases of confirmed lactic acidosis were 
reported to the Food and Drug Administration and of 
these just four patients were on metformin without any 
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other risk factors for lactic acidosis
10
. However, most 
patients in this study received metformin in the absence 
of routinely recommended contraindications. 
Metformin use has increased especially among patients 
with renal impairment and heart failure, which carries the 




Inappropriate metformin prescription for patients with 
heart failure or serum creatinine levels ≥150 mg/L varied 
from 4.5% to 38%, and the prevalence of underlying 
disorders predisposing to hyperlactatemia was >50%
14,15
. 
In patients with heart failure, although the underlying 
condition can predispose to LA, existing evidence 
suggests that metformin is associated with improved 
outcome rather than increased risk
16
. When risk factors 
are present, LA is more frequently reported. One of the 
important factors in evaluating the possibility of LA is 
renal function. Renal impairment may be present before 
or induced by intravascular CM administration. 
A cohort study compared 223,968 metformin users and 
34,571 patients with diabetes (2004–2012) who had 
never used metformin
17
. The risk of LA or elevated 
lactate concentrations was significantly increased in 
patients with severe renal insufficiency (eGFR <60 
mL/min/1.73 m
2
), and this risk was further increased 
with long-term heavy metformin treatment. Similar 




In this study, there was a significantly increased risk of 
LA in patients with cumulative exposure to metformin of 
≥730 g in the previous year, and in patients recently 
prescribed a daily dose of >2 g metformin. Compared 
with never users of metformin, there was a ~12-fold 
increased risk of LA in patients with reduced renal 
function and cumulative exposure to ≥730 g metformin 
in the preceding year. There was a ~13-fold increased 
risk of LA in patients with reduced renal function and 
recent exposure to >2 g/day metformin. 
Renal impairment and high cumulative and daily use of 
metformin, which both cause higher drug concentrations, 
attributed to an increased hazard of LA or elevated serum 
lactate level
7
. It is particularly interesting that the risk 
was further increased when both reduced renal function 
and high intake of metformin were present. The authors 
reported that they were not able to identify and exclude 
the exact causes of LA. 
In a cohort study with >51,000 patients with type 2 
diabetes, the effect of different degrees of renal function 
on the safety of metformin was evaluated
17
. When 
metformin use was compared with any other treatment, 
the risk of acidosis or serious infection was not 




Another investigation used HPLC to measure plasma 
metformin level in 14 patients who experienced LA (pH 
<7.35 and lactate concentration >5 mmol/L) while they 
were on chronic metformin treatment
18
. There was a 
positive correlation between serum creatinine and plasma 
metformin concentration. However, arterial lactate 
increased significantly just in patients with metformin 
accumulation who had moderate to severe renal failure. 
Almost all 14 patients with M-ALA had an underlying 
hypoxic condition. Metformin accumulation did not 
predict survival; rather, the prognosis was dependent 
upon the severity of the associated comorbidities. 
A similar recent study evaluating the prognostic effect of 
metformin serum concentration on M-ALA, confirmed 
this conclusion. Of 16 patients developing MALA while 
taking metformin, 11 (69%) had other risk factors for LA 
including renal failure or heart disease. Metformin serum 
concentration was higher in survivors whom had less 
sever concomitant underlying disorder. So the severity of 
such underlying disorders might have more significant 




M-ALA may occur in patients with previously normal 
renal function, even in young patients. Predisposing 
factors might be gastrointestinal discomfort or any 
concomitant disease that affects renal perfusion. In a 
study by Bruijstens et al., three patients with previously 
normal renal function developed serious M-ALA in the 
absence of chronic renal impairment
19
. The findings 
suggest that practitioners should keep any other 
contraindications of metformin in mind other than renal 
impairment or heart disease. 
Evidence of LA in patients on metformin receiving 
intravascular CM is based on some case reports and case 
series. Some authors believe that if renal function is 
normal, concomitant metformin use with intravascular 
CM might not be challenging. In a case series of 33 
patients receiving metformin, serum creatinine level did 
not increased in none of 29 patients with normal renal 
function post angiography
20
. In contrast, four patients 
who had an abnormal serum creatinine level before the 
procedure died. Two of the deaths were because of acute 
renal failure and LA. .In another group of 97 patients 
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receiving metformin, the serum creatinine levels were 
measured to determine the appropriate time for 
evaluation of renal function after CM administration. 0f 
97 patients with diabetes mellitus and normal renal 
function who received contrast media, 8 patients (~8%) 
had minor increase in creatinine level which required 
further monitoring and evaluation of metformin therapy 
and of them 4 patients (~4%) developed contrast induced 
nephropathy 
21
. In a clinical trial on a small group of 50 
patients exposed to CM with normal serum creatinine 
level, no accumulation of metformin was observed by 
ultra-high-performance chromatography tandem mass 
spectrometry 
22
. Also, there was no significant difference 
between the calculated creatinine clearance before and 48 
h after exposure. According to this patient population, 
interruption of metformin therapy during exposure to CM 
might not be necessary. 
Concerns about MALA after exposure to intravascular 
CMs in patients with normal serum creatinine level are 
raised by some case reports. Some alarming issues 
remain in such cases, like excess dose of CM, which 
might be a risk factor for MALA, as it induces a higher 
rate of contrast nephropathy. Jain et al. reported one fatal 
M-ALA that was triggered by CM-induced 
nephrotoxicity in a patient who had normal renal function 
before imaging. The patient underwent two CT scans 
with intravenous and a digital subtraction angiography 
with intra-arterial CM administration to evaluate the 
cause of subarachnoid haemorrhage. Overload of CM 
used in a rather short duration of 36h is probably 
responsible for such a poor outcome
23,24
. 
There is little evidence suggesting that metformin is a 
determining cofactor for the development of LA in 
patients with known predisposing conditions like renal or 
heart failure
5
. It is also suggested that in many cases of 
MALA that occurred after administration of intravascular 
CM, there was either pre-existing poor renal function or 
another contraindication to metformin usage
25
. 
Goergen et al. carried out a systematic review of 
guidelines evaluating the risk of LA after administration 
of CM in patients receiving metformin
24
. There was no 
evidence to discontinue metformin or retest renal 
function after CM administration in patients with normal 
baseline renal function who received a moderate load of 
CM.  
As the results of researches and guidelines are 
inconsistent, there are variable clinical practices. In a 
survey on UK physicians, 88% routinely suspended 
metformin prior to coronary angiography, irrespective of 
baseline renal function, and 28% felt that discontinuing 
metformin did not make a significant effect on outcome. 
Of those who discontinued metformin, there was no 
consensus about the discontinuation period, accordingly 
of all, 9% stopped taking metformin over 48 hours prior 
to procedure, 45% stopped 48 hours prior to procedure, 
17% stopped 24 hours prior to procedure, and 28% 
stopped on the day of the procedure. Of all, 94% did not 
routinely check renal status post-procedure unless there 
was an abnormal pre-procedural result, for instance in a 
pre-admission clinic measurement. Re-continuation time 
ranged from 24 hours (17%) to more than 48 hours 
(19%) post-procedure. The mentioned study 




Guidelines: American College of Radiology guidelines 
classifies patients taking metformin based on their renal 
function status and presence of comorbidities including 
causes of decreased metabolism of lactate (like liver 
dysfunction and alcohol abuse) and causes of increased 
anaerobic metabolism (such as cardiac failure, 
myocardial or peripheral muscle ischemia and sepsis or 
sever infection). Patients with normal renal function and 
without known comorbidities can continue taking 
metformin while receiving intravenous iodinated contrast 
medium and there is no need to recheck serum creatinine 
level following the procedure. Patients with multiple 
comorbidities and normal renal function should 
discontinue metformin at the day of the procedure and 
suspend it for 48 hours. A repeat serum creatinine is not 
necessary, although the follow-up procedure should be 
considered. Patients who are known to have renal 
dysfunction should stop metformin at the time of contrast 




According to Royal College of Radiologist guideline, 
there is not necessary to stop metformin in patients with 
normal serum creatinine and/or eGFR>60 ml/min/1.73 
m
2
. in other cases, any decision to suspend metformin for 
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Canadian Association of Radiologists Guideline 
recommends that patients with normal renal function can 
continue taking metformin without retest renal function 
following administration of up to 100mL of contrast 
medium. In patients with eGFR < 45 ml/min/1.73 m
2
, 
metformin should be stopped at the time of contrast 
administration and should not be restarted for at least 48 
hours only if renal function remains stable (less than 25% 
increase from baseline creatinine). Patients with marked 
renal impairment (eGFR<30 ml/min/1.73 m
2
) or acute 
kidney injury should stop metformin 48 hours prior to 
contrast administration; in addition, they should be 
reassessed for the indication of metformin use
29
.  
According to Royal Australian and New Zealand College 
of Radiologists, it is not necessary to stop metformin in 
patients with normal renal function, while a moderate 
Table 1: Summary of guidelines on administration of contrast media in diabetic patients taking metformin
7-31
. 
 ACR  CAR ESUR PCR RANZCR  
What is definition for renal 
impairment? 










When metformin should be 
discontinued in patients with 
normal renal function? 
No need  













When metformin should be 
discontinued in patients with 
abnormal renal function 
(pre-exposure to contrast 
administration)? 




mL/min/1.73 m2: at 




m2<30 or AKI: 48 






















Consultation  at the time 
of contrast 
exposure 
How long metformin should 
be suspended in patients with 
abnormal renal function 
(post-exposure to contrast 
administration)? 
No need 1.at least 48h 
2.reassess 
metformin use 
1. no need 
2. 48h after contrast 
exposure 
3.  metformin is 
contraindicated 
At least 48h At least 48h 
When renal function should 
be rechecked to restart 











cautious F/U of 
renal function 
1. normal renal 
function: no need 
2.abnormal renal 
function: 48 hours 
after contrast 
exposure 
1. normal renal 
function(eGFR≥60 
mL/min/1.73 m2- 
IA and eGFR≥45 
mL/min/1.73 m2-
IV): no need 
2.abnormal renal 
function: 48 hours 
after contrast 
exposure 










ACR, American College of Radiology; CAR, Canadian Association of Radiologists; ESUR, European Society of Urogenital Radiology; 
RCR, The Royal College of Radiologists; RANZCR, The Royal Australian and New Zealand College of Radiologists; eGFR, estimated 
glomerular filtration rate; SCr, serum creatinine. 
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amount of contrast is used (less than 100mL). Also, there 
is no need to retest renal function. In patients with renal 
impairment, metformin should be withheld for at least 48 
hours since the day of the contrast administration. Renal 




European Society of Urogenital Radiology guideline 
adopts a conservative approach and recommends holding 
metformin at the time of injection in patients with normal 
serum creatinine (eGFR ≥60 ml/min/1.73 m
2
) and 48 
hours prior to injection for elective studies in patients 
with abnormal renal function. Patients receiving 
intravenous contrast medium with eGFR ≥45 
ml/min/1.73m² can continue taking metformin normally 
but patients receiving intra-arterial contrast medium, and 
those receiving intravenous contrast medium with an 
eGFR between 30 and 44 ml/min/1.73 m², should stop 
metformin 48 hours prior to CM administration and 
should only restart metformin 48 hours after exposure if 
renal function is stable. In patients with eGFR less than 
30 ml/min/1.73 m² or with current illness causing 
impaired liver function or hypoxia, metformin is 
contraindicated and iodine-based contrast medium should 
be avoided. In emergency patients with unknown eGFR, 
metformin should be stopped from the time of exposure. 
After the procedure, signs of lactic acidosis should be 
monitored and metformin should be restarted 48 hours 
after contrast medium administration if serum 




Table 1 presents a comparison between different 
guidelines on CM administration in diabetic patients 
taking metformin. Although the recommendations vary 
among guidelines, most of them recommend not 
suspending metformin use in patients with normal renal 
function before the use of iodinated CM. 
Discussion 
Intravenous CMs are known to increase the risk of acute 
renal insufficiency. It is still controversial whether 
metformin accumulation itself is the only factor 
responsible for M-ALA. The only evidence which 
indicates that metformin use is associated with LA comes 
from reports of ~330 cases that have occurred in patients 
while on metformin treatment
3
. Taking these cases into 
consideration and according to expert opinion on 
metformin pharmacokinetics, conservative approach 
continues, but there are not strong academic evidences 
supporting current recommendations about the need to 
stop metformin administration and retest kidney function 
after intravascular CM administration; furthermore, the 
recommendations vary among professional international 
radiological organizations. However, latest guidelines are 
more consistent with each other than before. Although 
most cases of LA occurred in patients with abnormal 
renal function, LA seems to be rare in patients with 
normal baseline renal function before CM administration.  
In addition, intra-arterial CM injection in interventional 
cardiac, cerebral or peripheral CT angiography might 
raise the risk of contrast-induced nephropathy. Gruberg 
et al. showed contrast induced nephropathy developed in 




However, comparison of the risk of M-ALA after intra-
arterial vs intravenous CM injection should be evaluated 
in patients with normal baseline renal function taking 
metformin 
Conclusion 
There appears to be a contradiction between 
pharmaceutical companies and clinicians regarding 
discontinuation of metformin in the setting of iodinated 
CM administration, with the former insisting upon 
cessation regardless of the patient‘s clinical situation. 
However, clinicians whose opinions are reflected in 
various guidelines tend to have a less conservative 
approach. Taking all the above discussion into 
consideration, the following appears to be a reasonable 
approach.  
 It appears to be safe to continue metformin in patients 
with normal renal function (eGFR >60 mL/min/1.73 m
2
) 
and no other comorbidity.  
 In cases of renal function impairment (eGFR <30 
mL/min/1.73 m
2
), metformin should be discontinued and 
the indication to perform investigations with iodinated 
intravascular CM injection should be reassessed.  
 In patients with equivocal renal function (30 
mL/min/1.73 m
2
< eGFR <60 mL/min/1.73 m
2
) and those 
with normal renal function and other comorbidity, the 
decision to withhold metformin (prior to or at the time of 
the examination) and when to reinstate metformin should 
be based on the patient‘s clinical setting. This can only be 
achieved when there is clear and effective 
communication between the referring clinician, 
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radiologist and patient. 
 Metformin therapy should be stopped if renal function 
deteriorates acutely. This deterioration is demonstrated 
by elevation of serum creatinine level to ≥1.5 mg/dL in 
men and ≥1.4 mg/dL in women 48–72 h after the 
procedure, or by development of CM-associated 
nephropathy. So, laboratory follow-up seems to be 
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